Epigenomics AG
EPGNF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $386 | $524 | $563 | $559 |
| - Cash | $2,104 | $2,104 | $3,584 | $6,887 |
| + Debt | $11,889 | $11,889 | $356 | $439 |
| Enterprise Value | $10,171 | $10,309 | -$2,665 | -$5,889 |
| Revenue | $67 | $68 | $70 | $134 |
| % Growth | -1.5% | -2.7% | -47.8% | – |
| Gross Profit | $60 | $61 | $65 | $96 |
| % Margin | 89.6% | 89.8% | 92.9% | 71.6% |
| EBITDA | $190 | $2,564 | -$2,046 | -$4,322 |
| % Margin | 283.2% | 3,764.9% | -2,922.9% | -3,225.4% |
| Net Income | $1,880 | $1,880 | -$2,633 | -$5,591 |
| % Margin | 2,801.6% | 2,760.4% | -3,761.4% | -4,172.4% |
| EPS Diluted | 2.2 | 2.2 | -3.09 | -6.55 |
| % Growth | 0% | 171.2% | 52.8% | – |
| Operating Cash Flow | $374 | $374 | -$3,177 | -$3,282 |
| Capital Expenditures | $5 | $5 | -$1 | -$12 |
| Free Cash Flow | $379 | $379 | -$3,178 | -$3,294 |